Physician profile
Michelle DO
NPI 1053949446
$2,134.85
in general payments reported to CMS, 2019-2025
14 companies · $819 in 2025
The $819 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.87 · 2022: $439 · 2023: $391 · 2024: $471 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,680.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $352.40 | 2022-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $338.25 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $270.35 | 2023-2025 | Precision 1, Precision7, Dailies Total1 |
| Biotissue Holdings INC. | $211.00 | 2023-2025 | |
| Bausch & Lomb Americas INC. | $209.87 | 2022-2025 | Infuse, Miebo, Xiidra |
| Harrow Eye, LLC | $191.10 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $155.35 | 2022-2023 | Tyrvaya |
| Abbvie INC. | $102.16 | 2022-2025 | |
| Coopervision INC. | $88.66 | 2023-2025 | Misight Contact Lens, Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $82.28 | 2023-2025 | Cequa |
| Dompe US, INC. | $72.85 | 2022-2025 | Oxervate |
| Horizon Therapeutics Plc | $27.97 | 2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $17.74 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.